Cargando…

Development and Comparison of Intramuscularly Injected Long-acting Testosterone Undecanoate Nano-/Microcrystal Suspensions with Three Different Particle Size

The aim of this study was to develop and compare the pharmacokinetic property of testosterone undecanoate (TU) nano-/microcrystal suspension with three different particle sizes after intramuscular (i.m.) administration. TU nano-/microcrystal suspensions were prepared by high pressure homogenization...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jia, Lihua, Xiao, Jiachao, Yang, Xi, Gao, Jing, Zhang, Hui, Yu, Fanglin, Zheng, Aiping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Shaheed Beheshti University of Medical Sciences 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8170747/ https://www.ncbi.nlm.nih.gov/pubmed/34400960 http://dx.doi.org/10.22037/ijpr.2019.14408.12370

Ejemplares similares

Optimal injection interval for testosterone undecanoate treatment of hypogonadal and transgender men
por: Shankara Narayana, Nandini, et al.
Publicado: (2021)

Recovery of Male Reproductive Endocrine Function Following Prolonged Injectable Testosterone Undecanoate Treatment
por: Shankara-Narayana, Nandini, et al.
Publicado: (2021)

Oral testosterone undecanoate is an effective treatment for micropenis therapy
por: Saenger, Paul, et al.
Publicado: (2021)

Suppression of spermatogenesis by testosterone undecanoate-loaded injectable in situ-forming implants in adult male rats
por: Zhang, Xiao-Wei, et al.
Publicado: (2016)

Occurrence of Pulmonary Oil Microembolism After Testosterone Undecanoate Injection: A Postmarketing Safety Analysis
por: Pastuszak, Alexander W., et al.
Publicado: (2020)

Strawberry Decreases Intraluminal and Intestinal Wall Hydrolysis of Testosterone Undecanoate
por: Zgair, Atheer, et al.
Publicado: (2021)

Safety Aspects and Rational Use of Testosterone Undecanoate in the Treatment of Testosterone Deficiency: Clinical Insights
por: Campbell, Katherine, et al.
Publicado: (2023)

A New Oral Testosterone Undecanoate Formulation Restores Testosterone to Normal Concentrations in Hypogonadal Men
por: Swerdloff, Ronald S, et al.
Publicado: (2020)

Comparative application of testosterone undecanoate and/or testosterone propionate in induction of benign prostatic hyperplasia in Wistar rats
por: An, Jinho, et al.
Publicado: (2022)

Anaphylaxis Triggered by Benzyl Benzoate in a Preparation of Depot Testosterone Undecanoate
por: Ong, Gregory S. Y., et al.
Publicado: (2012)

Corrigendum for: “A New Oral Testosterone Undecanoate Formulation Restores Testosterone to Normal Concentrations in Hypogonadal Men”
Publicado: (2020)

Exploring the efficacy of testosterone undecanoate in male children with 5α‐reductase deficiency
por: Liu, Ying, et al.
Publicado: (2021)

Effects of the oral testosterone undecanoate Kyzatrex™ on ambulatory blood pressure in hypogonadal men
por: White, William B., et al.
Publicado: (2021)

Importance of measuring testosterone in enzyme-inhibited plasma for oral testosterone undecanoate androgen replacement therapy clinical trials
por: Lachance, Sylvain, et al.
Publicado: (2015)

Effectiveness of a low dose testosterone undecanoate to improve sexual function in postmenopausal women
por: Tungmunsakulchai, Reuthairat, et al.
Publicado: (2015)

SUN-234 Effect of Testosterone Undecanoate on Metabolic Syndrome Parameters in a Cohort of Hypogonadism
por: Yadav, Subhash Chandra, et al.
Publicado: (2019)

A new oral testosterone undecanoate therapy comes of age for the treatment of hypogonadal men
por: Swerdloff, Ronald S., et al.
Publicado: (2020)

Spectrophotometric and chromatographic strategies for exploring of the nanostructure pharmaceutical formulations which contains testosterone undecanoate
por: Butnariu, Monica, et al.
Publicado: (2020)

Microfiltration of Submicron-Sized and Nano-Sized Suspensions for Particle Size Determination by Dynamic Light Scattering
por: Ullmann, Christian, et al.
Publicado: (2019)

Effects of Five-Year Treatment with Testosterone Undecanoate on Metabolic and Hormonal Parameters in Ageing Men with Metabolic Syndrome
por: Francomano, Davide, et al.
Publicado: (2014)

Corrigendum to a new oral testosterone undecanoate (TU) therapy comes of age for the treatment of hypogonadal men
Publicado: (2021)

Safety Analysis of an Oral Testosterone Undecanoate (TU) Formulation Following 2 Years of Administration in Hypogonadal Men
por: Swerdloff, Ronald S, et al.
Publicado: (2021)

Population Pharmacokinetic Modeling and Simulations to Evaluate a Potential Dose Regimen of Testosterone Undecanoate in Hypogonadal Males
por: Pastuszak, Alexander W., et al.
Publicado: (2021)

Effects of Low-Dose Testosterone Undecanoate Treatment on Bone Mineral Density and Bone Turnover Markers in Elderly Male Osteoporosis with Low Serum Testosterone
por: Wang, Yan-Jiao, et al.
Publicado: (2013)

Intra-Articular injection of acid-sensitive stearoxyl-ketal-dexamethasone microcrystals for long-acting arthritis therapy
por: Xu, Yang, et al.
Publicado: (2021)

Pharmacological treatment for pubertal progression in boys with delayed or slow progression of puberty: A small-scale randomized study with testosterone enanthate and testosterone undecanoate treatment
por: Österbrand, Martin, et al.
Publicado: (2023)

SAT-038 Ambulatory Blood Pressure Increases in Hypogonadal Men Who Develop Increases in Hematocrit on Oral Testosterone Undecanoate
por: Dobs, Adrian Sandra, et al.
Publicado: (2020)

Altered cardiac repolarization associated with cellular electrophysiological remodeling following chronic testosterone undecanoate administration in a canine model
por: Topal, L, et al.
Publicado: (2023)

SUN-227 Monitoring Testosterone (T) Levels in Men Receiving Oral Testosterone Undecanoate (TU): Challenges Due to Post-Collection Conversion of TU-to-T and a Path Forward
por: Swerdloff, Ronald, et al.
Publicado: (2019)

SUN-083 Hypertension and Hemodynamic Parameters in Men with Hypogonadism Improve Under Long-Term Treatment with Testosterone Undecanoate Injections (TU) Compared to Untreated Hypogonadal Control Patients
por: Saad, Farid, et al.
Publicado: (2019)

UGT2B17 Genotype and the Pharmacokinetic Serum Profile of Testosterone during Substitution Therapy with Testosterone Undecanoate. A Retrospective Experience from 207 Men with Hypogonadism
por: Bang, Anne Kirstine, et al.
Publicado: (2013)

PMON267 Comparison Between Single Time Point Testing and 24-Hour Average Concentration of Total Testosterone in Hypogonadal Men Treated with an Oral Testosterone Undecanoate Softgel (JATENZO®)
por: Swerdloff, Ronald, et al.
Publicado: (2022)

Metabolic phenotype of male obesity-related secondary hypogonadism pre-replacement and post-replacement therapy with intra-muscular testosterone undecanoate therapy
por: Dimitriadis, Georgios K., et al.
Publicado: (2018)

Testosterone undecanoate supplementation together with human chorionic gonadotropin does not impair spermatogenesis in males with isolated hypogonadotropic hypogonadism: a retrospective study
por: Chen, Yin-Wei, et al.
Publicado: (2019)

Effects of testosterone undecanoate on performance during multi-stressor military operations: A trial protocol for the Optimizing Performance for Soldiers II study
por: Varanoske, Alyssa N., et al.
Publicado: (2021)

MON-091 Profound and Sustained Weight Loss in Men With Hypogonadism and Obesity Receiving Long-Term Testosterone Therapy (TTh) with Testosterone Undecanoate Injections (TU): 10-Year Data from a Registry Study in a Urological Setting
por: Haider, Karim, et al.
Publicado: (2019)

SUN-226 Improvements In Quality Of Life In Men With Hypogonadism Under Long-term Testosterone Therapy (TTh) With Testosterone Undecanoate Injections (TU): Experience From 6,500 Patient-years Ina Registry Study Ina Urological Setting
por: Haider, Karim, et al.
Publicado: (2019)

Importance of Particle Size-Fraction Analysis in Suspensions
por: Müller, Loretta, et al.
Publicado: (2010)

Rheology of Highly Concentrated Suspensions with a Bimodal Size Distribution of Solid Particles for Powder Injection Molding
por: Mityukov, Anton V., et al.
Publicado: (2021)

SAT-533 Men with Hypogonadism and Osteoporosis Benefit from Long-Term Testosterone Therapy (TTh) with Testosterone Undecanoate Injections (TU) Regardless of Co-Medication with Bisphosphonates: 10-Year Data from a Controlled Registry Study in a Urological Setting
por: Haider, Ahmad, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_mm3u0thekt57pbcvvk0qh6s1oj